New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 16, 2014
08:48 EDTBAXBaxter says meets primary endpoint in Phase 3 BAX 111 trial
Baxter International announced topline results from a Phase 3 clinical trial evaluating the safety, efficacy and pharmacokinetics of BAX 111. BAX 111 is a recombinant von Willebrand factor under investigation for the treatment of bleeding episodes in patients with von Willebrand disease, the most common type of inherited bleeding disorder. The study of BAX 111, the first recombinant treatment in clinical development for this condition, met its primary efficacy endpoint, as all patients achieved pre-specified success in the on-demand treatment of bleeding events. The Phase 3 multicenter, open-label clinical trial assessed the safety, efficacy and pharmacokinetics of BAX 111 administered together with ADVATE or as a stand-alone therapeutic agent in the on-demand treatment of 37 patients with severe von Willebrand disease at trial sites in the United States, Europe, Australia, Japan, Russia and India. The primary endpoint was the number of patients experiencing successful treatment for bleeding episodes. Secondary endpoints included additional efficacy and safety measures, pharmacokinetics and health-related quality of life. There were no reports of inhibitor development or thrombotic events in the study participants. The most common adverse events in the study were headache, vomiting/nausea and anemia (iron deficiency anemia), which were not considered to be related to treatment. There was one serious adverse event related to treatment, characterized by chest discomfort and increased heart rate during infusion, which rapidly resolved without further complication. The investigational treatment was developed using a plasma- and albumin-free manufacturing method.
News For BAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 10, 2016
07:15 EDTBAXLeerink to hold a conference
Subscribe for More Information
February 2, 2016
09:24 EDTBAXBaxter: 1Q16 should be weakest quarter of FY16
Subscribe for More Information
08:53 EDTBAXBaxter sees FY16 CapEx $900M
Says does not anticipate any sales in 2016 in IPS. Sees FY16 surgical franchise sales growth 2%-3%. Sees FY16 renal business sales growth roughly 3%. Sees FY16 operating margin roughly 11%. Sees FY16 interest expense roughly $90M. Sees FY16 adjusted tax rate 19%-20%. Sees FY16 average share count roughly 540M shares. Sees FY16 CapEx $900M. Sees FY16 free cash flow $500M. Sees FY16 operating cash flow roughly $1.4B. Guidance taken from Q4 earnings conference call.
07:04 EDTBAXBaxter sees FY16 EPS ex-items $1.46-$1.54, consensus $1.42
Subscribe for More Information
07:03 EDTBAXBaxter sees Q1 EPS ex-items 28c-30c, consensus 32c
Subscribe for More Information
07:02 EDTBAXBaxter reports Q4 adjusted EPS 43c, consensus 32c
Subscribe for More Information
February 1, 2016
14:32 EDTBAXNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Exxon Mobil (XOM), consensus 64c... Pfizer (PFE), consensus 52c... United Parcel Service (UPS), consensus $1.42... Dow Chemical (DOW), consensus 70c... Emerson Electric (EMR), consensus 51c... Archer-Daniels-Midland (ADM), consensus 66c... Baxter (BAX), consensus 32c... Sirius XM (SIRI), consensus 3c... Royal Caribbean Cruises (RCL), consensus 92c... Ally Financial (ALLY), consensus 51c... Michael Kors (KORS), consensus $1.46... ADT Corp. (ADT), consensus 46c.
08:09 EDTBAXOptions expected to be active
Options expected to be active: GOOGL GOOG YHOO UPS KORS UPS BAX RCL CCL PFE AET D STR DWA CMG ABT SYK.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use